- Acumen Powered by Robins Kaplan LLP®
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
June 17, 2024Emily Tremblay Named IP Rising Star by Euromoney in 2024 Women in Business Law Awards
-
June 17, 2024Three Robins Kaplan Partners Named BTI Client Service All-Stars
-
June 13, 2024Brendan Johnson Named South Dakota Trial Lawyer of The Year
-
June 27, 2024Sex Abuse Litigation
-
June 10-11, 20242024 Probate and Trust Law Section Conference
-
June 11, 2024FBA 2024 Federal Practice Seminar
-
June 2024Robins Kaplan Secures Landmark $7.75 Million Verdict in Aerosol Duster Misuse Case
-
June 2024To Seize or Not to Seize: Campus Protests and Police Uses of Force
-
June 2024Communicating Your Estate Plan: A Helpful Tool, Not a Fix-All
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Avanir Pharms., Inc. v. Actavis South Atlantic LLC (D. Del.)
Defendants did not meet their burden of showing that all three patents-in-suit are invalid as obvious, and stipulated to infringement of two of three of those patents.
Summer 2014
Case Name: Avanir Pharms., Inc. v. Actavis South Atlantic LLC, Case No. 1:11-cv-0704-LPS, 2014 U.S. Dist. LEXIS 67111 (D. Del. May 5, 2014) (Stark, J.)
Drug Product and Patent(s)-in-Suit: Nuedexta® (dextromethorphan/quinidine); U.S. Pats. Nos. RE38,115 (“the ’115 patent”), 7,659,282 (“the ’282 patent”), and 8,227,484 (“the ’484 patent”)
Nature of the Case and Issue(s) Presented: The ’115 patent relates to formulations containing dextromethorphan and quinidine for the treatment of chronic or intractable pain. The ’282 and ’484 patents relate to the use of dextromethorphan and quinidine for the treatment of a neurological disorder known as pseudobulbar affect (“PBA”). Defendants stipulated that their proposed products infringe claims 1-9 of the ’282 patent and claims 1-9, 12, 13, 15, and 17 of the ’484 patent. After a six-day bench trial, the court found that: (i) plaintiffs have not proven by a preponderance of the evidence that defendants infringe claims 18-21 of the ’115 patent, (ii) defendants have failed to prove by clear and convincing evidence that claims 1-9 of the ’282 patent are invalid; (iii) defendants have failed to prove by clear and convincing evidence that claims 1-9, 12, 13, 15, and 17 of the ’484 patent are invalid; and (iv) defendants have failed to prove by clear and convincing evidence that claims 18-21 of the ’115 patent are invalid.
Why Avanir Prevailed: Concerning whether defendants’ ANDA products infringed the ’115 patent, the dispute focused on whether Nuedexta contains a combined unit dosage of dextromethorphan and quinidine that is “therapeutically effective in substantially reducing chronic or intractable pain, without unacceptable side effects.” Nuedexta has been approved by the FDA only to treat PBA. Its package insert provides no statement on treating pain, and none of the Nuedexta clinical studies establish that Nuedexta is “therapeutically effective” in substantially reducing chronic pain. Avanir’s reliance on patient interviews, which are undocumented and lack objective measures of efficacy, provided little evidence in support of its infringement theory. Moreover, studies measuring the response to Nuedexta among normal subjects experiencing pain are only minimally relevant to whether Nuedexta can effectively treat patients with chronic or intractable pain without causing unacceptable side effects. Therefore, defendants’ ANDA products do not infringe the asserted claims of the ’115 patent.
Concerning whether the prior art renders the ’484 and ’282 patents obvious, defendants argued that the only difference between the prior art and the asserted claims is the dose ranges of quinidine. This, however, ignores the subject matter of the claims as a whole, including the amounts of dextromethorphan and the claimed weight to weight ratios of dextromethorphan and quinidine. Defendants also argued that a person or ordinary skill would have been motivated to modify the dose of quinidine because of safety concerns and industry practice. The court disagreed. Defendants’ evidence for cardiotoxicity pertained only to the far higher antiarrhythmic dose levels of quinidine and the other side effects were associated with dextromethorphan rather than quinidine. In any event, any remaining safety concerns about quinidine taught a person of ordinary skill either to obtain only the lowest efficacious dose or to discontinue use of quinidine altogether. The court found that there would also be no reasonable expectation of success when lowering the dose of quinidine because as a general matter, central nervous system drug development is “challenging and unpredictable, especially in relation to treatment PBA, a disease for which the mechanism for treatment remains unknown.” Next, the court addressed secondary considerations of non-obviousness. The court concluded that a nexus existed between Nuedexta’s commercial success and the claimed invention. It also found that Avanir presented evidence of unexpected safety benefits and unexpected efficacy in the treatment of PBA.
Finally, since defendants failed to proffer any evidence that a person of ordinary skill would have found the claimed invention of the ’115 patent obvious in light of the “therapeutically effective” limitation, the court concluded that defendants had not shown, by clear and convincing evidence, that the asserted claims of the ’115 patent are obvious.
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.